Evidence map›Paper›PMID 40572374›Full record

ArticleMicromachines2025

Bioprinting of GelMA-Based Hydrogels to Aid in Creation of Biomimetic 3D Models for Glioblastoma.

Kaitlyn Ann Rose Schroyer, Kylie Marie Schmitz, Gunjeeta Raheja, Bin Su, Justin D Lathia, Liqun Ning

Abstract read
In one paragraph

Article in Micromachines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Modeling pediatric brain tumors with human stem cells.Frontiers in cellular neuroscience · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaitlyn Ann Rose SchroyerDepartment of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, OH 44115, USA.
Kylie Marie SchmitzDepartment of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, OH 44115, USA.ORCID 0009-0003-5550-2024
Gunjeeta RahejaDepartment of Mechanical Engineering, Cleveland State University, Cleveland, OH 44115, USA.
Bin SuCenter for Gene Regulation in Health and Disease, Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA.
Justin D LathiaCase Comprehensive Cancer Center, Cleveland, OH 44106, USA.
Liqun NingDepartment of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, OH 44115, USA.

Funding

Cleveland State University Startup Grant and Faculty Research and Development (FRD) GrantU.S. National Science Foundation No.1126126
6 · The paper itself

Abstract

Glioblastoma (GBM, isocitrate dehydrogenase wild-type) is the most common primary malignant brain tumor in adults and is associated with a severely low survival rate. Treatments offer mere palliation and are ineffective, due, in part, to a lack of understanding of the intricate mechanisms underlying the disease, including the contribution of the tumor microenvironment (TME). Current GBM models continue to face challenges as they lack the critical components and properties required. To address this limitation, we developed innovative and practical three-dimensional (3D) GBM models with structural and mechanical biomimicry and tunability. These models allowed for more accurate emulation of the extracellular matrix (ECM) and vasculature characteristics of the native GBM TME. Additionally, 3D bioprinting was utilized to integrate these complexities, employing a hydrogel composite to mimic the native environment that is known to contribute to tumor cell growth. First, we examined the changes in physical properties that resulted from adjoining hydrogels at diverse concentrations using Fourier-Transform Infrared Spectroscopy (FTIR), compression testing, scanning electron microscopy (SEM), rheological analysis, and degradation analysis. Subsequently, we refined and optimized the embedded bioprinting processes. The resulting 3D GBM models were structurally reliable and reproducible, featuring integrated inner channels and possessing tunable properties to emulate the characteristics of the GBM ECM. Biocompatibility testing was performed via live/dead and AlamarBlue analyses using GBM cells (both commercial cell lines and patient-derived cell lines) encapsulated in the constructs, along with immunohistochemistry staining to understand how ECM properties altered the functions of GBM cells. The observed behavior of GBM cells indicated greater functionality in softer matrices, while the incorporation of hyaluronic acid (HA) into the gelatin methacryloyl (gelMA) matrix enhanced its biomimicry of the native GBM TME. The findings underscore the critical role of TME components, particularly ECM properties, in influencing GBM survival, proliferation, and molecular expression, laying the groundwork for further mechanistic studies. Additionally, the outcomes validate the potential of leveraging 3D bioprinting for GBM modeling, providing a fully controllable environment to explore specific pathways and therapeutic targets that are challenging to study in conventional model systems.

Indexed as

3D bioprintingextracellular matrixGBM modelingglioblastomahydrogelstumor microenvironment

Identifiers

PMID40572374
PMCPMC12194998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.